Edgewise Therapeutics Doses First Patient In Phase 2 CIRRUS-HCM Trial Of EDG-7500 In Obstructive Hypertrophic Cardiomyopathy
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCMtrial of EDG-7500. EDG-7500 is a novel oral,